Investigator Sponsored Trials (ISTs) are clinical & pre-clinical (in-vitro and in-vivo) studies initiated and managed by a non-pharmaceutical company researcher (individual investigator, institution, cooperative group, etc) who is responsible for the conduct, oversight, and management of the IST (as the Sponsor Investigator). Genmab acts as a supporter to provide funding and product and in some instances collaboration to pursue regulatory strategy. These can include both interventional and non-interventional (observational, real-world evidence) studies, pre-clinical in vitro research projects, and studies/analyses performed on banked clinical samples.
The portal is now open for proposal submissions, reconciliations, and status inquiries. Genmab is committed to expeditiously reviewing and processing proposals. You will be promptly notified of our decision.
Prior to submitting your proposal request, please be sure to review our “Areas of Interest” section below. Also, at the top of the page, you will want to familiarize yourself with “Our Process” and “How to Apply” sections.
For any questions related to the study process and/or submissions please email ISTs@genmab.com.
Collaborative Studies are interventional or non-interventional study conducted by Genmab and a Collaborative Study Partner who are pursuing mutually beneficial prospective human research generating primary data. Collaborative Studies are sponsored by one of the Collaborative Study Partners. In Collaborative Studies, the Collaborative Study Partner acting as the Sponsor must transfer at least one of Sponsor related duties and functions (e.g., study design input, preparation, labelling and distribution of study product, interpretation of data, etc.) to be performed by Genmab. Collaborative Study concepts may be initiated by Genmab or the Collaborative Study Partner.
The portal is now open for proposal submissions, reconciliations, and status inquiries. Genmab is committed to expeditiously reviewing and processing proposals. You will be promptly notified of our decision.
Prior to submitting your proposal request, please be sure to review our “Areas of Interest” section below. Also, at the top of the page, you will want to familiarize yourself with “Our Process” and “How to Apply” sections.
For any questions related to the study process and/or submissions please email CollaborativeStudies@genmab.com.
Epcoritamab is a a subcutaneous CD3xCD20 bispecific antibody that is being investigated in a number of hematological indications, including but not limited to: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL).
Priority will be given to epcoritamab applications proposing to investigate the following areas:
Pre-clinical and translational applications will be reviewed to prioritize proposals aligned to the following goals:
Tisotumab vedotin
Tisotumab vedotin is an antibody drug conjugate (ADC) that targets tissue factor (TF).
Consideration will be given to both preclinical and clinical applications in the following areas:
To apply for an IST related to tisotumab vedotin in the US, please visit the Pfizer Competitive Grants Portal
To apply for an IST related to tisotumab vedotin in Japan and EU, please continue here.